Project profile — Global Drug Facility: Provision of Anti-Tuberculosis Drugs


United Nations Office for ProjectServices: Stop TB Partnership (41502)
2010-03-20 - 2020-02-11
Global Affairs Canada
MFM Global Issues & Dev.Branch

Country / region 

• Africa, regional (35.00%)
• America, regional (1.00%)
• Asia, regional (61.00%)
• Europe, regional (3.00%)


• Basic Health: Tuberculosis control (12263) (100.00%)

Policy marker 

• Gender equality (not targeted)
• Environmental sustainability (cross-cutting) (not targeted)
• Participatory development and good governance (not targeted)
• Trade development (not targeted)
• Biodiversity (not targeted)
• Climate change mitigation (not targeted)
• Climate Change Adaptation (not targeted)
• Urban issues (not targeted)
• Desertification (not targeted)
• Children's issues (not targeted)
• Youth Issues (not targeted)
• Indigenous Issues (not targeted)
• Disability (not targeted)
• ICT as a tool for development (not targeted)


This grant represents part of Canada’s contribution to the Global Drug Facility (GDF), a program of the Stop TB Partnership. It provides access to anti-tuberculosis (TB) drugs for governments that agree to introduce, expand, or maintain the diagnostic, treatment, and monitoring policies of the DOTS (directly observed treatment, short-term) strategy. Launched in 2001, the GDF works to improve the supply, distribution, and monitoring of anti-TB drugs in developing countries and is the only global bulk procurer of anti-TB drugs. Canada was the founding donor of the GDF and to date (2010) has been the single largest donor country for first-line TB drugs. The GDF is a four-pronged mechanism whereby: (1) countries who cannot afford to procure all the anti-TB drug they need are eligible to apply for drugs for up to six years (DFATD provides funding for this component); (2) countries who can pay for the anti-TB drugs they need but cannot assure the quality of the drugs can directly procure them through the GDF at reduced bulk prices (DFATD funding does not contribute to this component); (3) countries where the procurement system is weak can receive technical assistance to strengthen their capacity for drug procurement (DFATD supports this component); and (4) Global Fund recipient countries can procure anti-TB drugs directly through GDF, using Global Fund monies, to ensure a stable and high-quality drug supply.

Expected results 


Results achieved 

Results achieved by Global Drug Facility, through the support of the Government of Canada and other international donors, as of March 2016 include: (1) provided quality-assured treatments since 2001 for more than 27 million patients with tuberculosis (TB), This included over 184,000 patient treatments for multi-drug resistant TB (MDR-TB) and 1.5 million treatments for children; (2) delivered over 1.5 million patient treatments, including over 219,000 pediatric treatments in 2015; (3) provided capacity-building support to 134 countries since 2001, including training and workshops, monitoring missions and technical assistance to improve the management of drug supplies; (4) contributed to planning and guidance for the global introduction of new child-friendly medicines for pediatric TB; and (5) provided a mechanism for countries to order the new pediatric formulations and made grants available to eligible countries to purchase pediatric TB medicines with funding from Global Affairs Canada.

Budget and spending 

Original budget $0
Planned disbursement $0
Country percentages by sector
Type of finance Aid grant excluding debt reorganisation
Collaboration type Bilateral
Type of aid Contributions to specific-purpose programmes and funds managed by implementing partners
Date modified: